Mackenzie Financial Has Trimmed Activision Blizzard (ATVI) Stake By $8.95 Million; Exelixis, Inc. (EXEL) Covered By 0 Bulls

September 14, 2018 - By Heather Owens

Activision Blizzard, Inc. (NASDAQ:ATVI) Logo

Mackenzie Financial Corp decreased Activision Blizzard Inc (ATVI) stake by 54.26% reported in 2018Q2 SEC filing. Mackenzie Financial Corp sold 117,820 shares as Activision Blizzard Inc (ATVI)’s stock rose 5.02%. The Mackenzie Financial Corp holds 99,327 shares with $7.58M value, down from 217,147 last quarter. Activision Blizzard Inc now has $61.59B valuation. The stock increased 0.44% or $0.36 during the last trading session, reaching $80.79. About 3.08M shares traded. Activision Blizzard, Inc. (NASDAQ:ATVI) has risen 21.83% since September 14, 2017 and is uptrending. It has outperformed by 6.21% the S&P500. Some Historical ATVI News: 04/05/2018 – Activision Blizzard: dead dangerous; 05/04/2018 – Prepare to Join the Battle for Azeroth™–New World of Warcraft® Expansion Arrives August 14; 03/05/2018 – ACTIVISION WILL ADD NEW PLAYER MODES TO GAMES IN FORTNITE WAKE; 03/05/2018 – Activision Blizzard releases early earnings after results leak; 12/03/2018 – Hearthstone® Players Can Unleash Their Inner Beast in Upcoming Expansion The Witchwood™; 29/05/2018 – Activision Blizzard Announces Sale of Special Call of Duty®: WWII Fear Not Pack to Support the Placement of Veterans into High; 22/05/2018 – Hasbro Joins Blizzard Entertainment’s Overwatch® in the Fight for the Future as Master Toy Licensee; 03/05/2018 – Correction to Activision Revenue Headline; 30/03/2018 – Call of Duty World League, Presented by PlayStation®4, Brings Competitive Season to United Kingdom; 12/03/2018 – Rise Nation Crowned Champion of the CWL Atlanta Open

Among 2 analysts covering Exelixis (NASDAQ:EXEL), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Exelixis had 3 analyst reports since May 3, 2018 according to SRatingsIntel. Stifel Nicolaus maintained the shares of EXEL in report on Thursday, May 3 with “Hold” rating. The stock has “Hold” rating by Stifel Nicolaus on Wednesday, August 1. See Exelixis, Inc. (NASDAQ:EXEL) latest ratings:

10/09/2018 Broker: Morgan Stanley Rating: Underweight New Target: $19 Initiates Coverage On
01/08/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $29 New Target: $25 Maintain
03/05/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $30 New Target: $29 Maintain

The stock increased 0.81% or $0.135 during the last trading session, reaching $16.845. About 1.97M shares traded. Exelixis, Inc. (NASDAQ:EXEL) has declined 38.03% since September 14, 2017 and is downtrending. It has underperformed by 53.65% the S&P500. Some Historical EXEL News: 22/05/2018 – Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy; 23/03/2018 – EXELIXIS’ PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA; 23/03/2018 – EXELIXIS INC EXEL.O – POSITIVE CHMP OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 15/03/2018 – Join Celestial Seasonings 8th Annual B Strong Ride; 24/05/2018 – Autodesk: celestial being; 08/05/2018 – Hain Celestial Expects to Complete Divestiture of Hain Pure Protein During 1H of Fiscal 2019; 08/05/2018 – HAIN CELESTIAL REITERATES ANNUAL NET SALES OUTLOOK; 15/03/2018 – EXEL REPORTS STATISTICALLY SIGNIFICANT IMPROVEMENT VS PLACEBO; 23/03/2018 – lpsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma; 08/05/2018 – HAIN CELESTIAL GROUP INC – UPDATES FISCAL 2018 EARNINGS GUIDANCE FOR CONTINUING OPERATIONS EXCLUDING HAIN PURE PROTEIN

Since April 11, 2018, it had 0 insider purchases, and 21 insider sales for $17.46 million activity. 14,959 shares were sold by WYSZOMIERSKI JACK L, worth $302,920. $447,200 worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by Hessekiel Jeffrey on Friday, May 4. $705,797 worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by FELDBAUM CARL B. $303,750 worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by Garber Alan M on Monday, April 16. MORRISSEY MICHAEL sold $1.87M worth of stock. Schwab Gisela also sold $519,417 worth of Exelixis, Inc. (NASDAQ:EXEL) on Thursday, May 3. $321,300 worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by COHEN CHARLES.

Investors sentiment increased to 1.28 in 2018 Q2. Its up 0.12, from 1.16 in 2018Q1. It increased, as 41 investors sold Exelixis, Inc. shares while 68 reduced holdings. 55 funds opened positions while 85 raised stakes. 234.21 million shares or 3.66% more from 225.93 million shares in 2018Q1 were reported. Vanguard Grp Inc accumulated 25.69M shares. Texas Permanent School Fund owns 165,669 shares or 0.05% of their US portfolio. Ing Groep Nv holds 0.02% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 43,198 shares. Daiwa Securities Group Inc holds 0% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL) for 1,635 shares. Bb&T Securities Ltd Com owns 12,000 shares. Deutsche Bancshares Ag owns 0.05% invested in Exelixis, Inc. (NASDAQ:EXEL) for 3.23M shares. Quantbot Technology L P invested 0.01% in Exelixis, Inc. (NASDAQ:EXEL). Seabridge Invest Advsrs Ltd Com owns 500 shares. Lpl Financial Ltd Company has invested 0% in Exelixis, Inc. (NASDAQ:EXEL). Schwab Charles Invest Management holds 0.02% or 1.02 million shares in its portfolio. Victory Capital owns 58,662 shares or 0% of their US portfolio. Renaissance Limited owns 0.08% invested in Exelixis, Inc. (NASDAQ:EXEL) for 3.15M shares. Prudential Financial has 401,530 shares for 0.01% of their portfolio. Brown Advisory Limited Liability Corp holds 20,000 shares. Great West Life Assurance Com Can holds 0% or 31,890 shares in its portfolio.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $5.02 billion. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 16.34 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

More notable recent Exelixis, Inc. (NASDAQ:EXEL) news were published by: Seekingalpha.com which released: “Exelixis: An Updated View” on September 14, 2018, also Seekingalpha.com with their article: “Exelixis’ Cabometyx expands presence in cancer care guidelines” published on September 07, 2018, Seekingalpha.com published: “Exelixis: Elucidating The Upcoming Clinical Binary For Cabozantinib” on September 06, 2018. More interesting news about Exelixis, Inc. (NASDAQ:EXEL) were released by: Fool.com and their article: “Why SandRidge Energy, Sonos, and Exelixis Slumped Today” published on September 11, 2018 as well as Seekingalpha.com‘s news article titled: “Exelixis: Existential Threats Linger Despite Growing Revenues” with publication date: August 22, 2018.

Mackenzie Financial Corp increased Axcelis Technologies Inc stake by 49,100 shares to 332,100 valued at $6.58 million in 2018Q2. It also upped Sherwin Williams Co (NYSE:SHW) stake by 194,202 shares and now owns 522,857 shares. First Solar Inc (NASDAQ:FSLR) was raised too.

Among 9 analysts covering Activision Blizzard (NASDAQ:ATVI), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Activision Blizzard had 10 analyst reports since May 1, 2018 according to SRatingsIntel. The rating was maintained by Barclays Capital on Monday, August 6 with “Equal-Weight”. As per Monday, June 18, the company rating was maintained by KeyBanc Capital Markets. J.P. Morgan initiated the stock with “Hold” rating in Tuesday, May 1 report. Bank of America downgraded the stock to “Neutral” rating in Friday, August 31 report. On Wednesday, July 11 the stock rating was maintained by Morgan Stanley with “Overweight”. As per Friday, May 4, the company rating was maintained by William Blair. Bank of America maintained Activision Blizzard, Inc. (NASDAQ:ATVI) rating on Friday, May 4. Bank of America has “Buy” rating and $76 target. The firm has “Outperform” rating given on Friday, May 4 by Credit Suisse. As per Friday, May 4, the company rating was maintained by Stifel Nicolaus.

Investors sentiment increased to 1.2 in 2018 Q2. Its up 0.30, from 0.9 in 2018Q1. It is positive, as 51 investors sold ATVI shares while 222 reduced holdings. 95 funds opened positions while 232 raised stakes. 644.93 million shares or 0.98% more from 638.65 million shares in 2018Q1 were reported. Palo Incorporated holds 0.23% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI) for 8,146 shares. Richard Bernstein Lc owns 57,317 shares. Kentucky Retirement Sys reported 0.25% stake. Advisory Net Ltd Liability stated it has 5,720 shares or 0.03% of all its holdings. Usca Ria Ltd Company holds 0.04% or 5,012 shares. D E Shaw & Inc holds 0.08% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI) for 761,088 shares. Moreover, First Trust Advisors Lp has 0.09% invested in Activision Blizzard, Inc. (NASDAQ:ATVI) for 544,647 shares. Partner Fund Mgmt LP accumulated 552,659 shares. Wafra invested 0.61% in Activision Blizzard, Inc. (NASDAQ:ATVI). Bank Of New York Mellon Corp stated it has 0.16% of its portfolio in Activision Blizzard, Inc. (NASDAQ:ATVI). Moreover, Suntrust Banks has 0.04% invested in Activision Blizzard, Inc. (NASDAQ:ATVI) for 88,545 shares. Fulton Bancorporation Na owns 14,715 shares for 0.08% of their portfolio. Arizona State Retirement System has invested 0.14% in Activision Blizzard, Inc. (NASDAQ:ATVI). Moreover, American Natl Ins Tx has 0.35% invested in Activision Blizzard, Inc. (NASDAQ:ATVI). New York-based Oppenheimer Company has invested 0.11% in Activision Blizzard, Inc. (NASDAQ:ATVI).

More notable recent Activision Blizzard, Inc. (NASDAQ:ATVI) news were published by: Nasdaq.com which released: “Gaming Stocks: How to Trade a Downtrodden EA and ATVI” on August 22, 2018, also Nasdaq.com with their article: “King’s First RPG Expands Activision’s (ATVI) Mobile Portfolio” published on August 17, 2018, Livetradingnews.com published: “Activision Blizzard, Inc. (NASDAQ:ATVI) soars after gamers cheer new battle royale ‘Call of Duty'” on September 12, 2018. More interesting news about Activision Blizzard, Inc. (NASDAQ:ATVI) were released by: Nasdaq.com and their article: “5 Top Stock Trades for Wednesday — Buy Nike and Sonos?” published on September 12, 2018 as well as Seekingalpha.com‘s news article titled: “Twitter seals Overwatch League content deal” with publication date: August 23, 2018.

Analysts await Activision Blizzard, Inc. (NASDAQ:ATVI) to report earnings on November, 1. They expect $0.47 earnings per share, up 9.30% or $0.04 from last year’s $0.43 per share. ATVI’s profit will be $358.31M for 42.97 P/E if the $0.47 EPS becomes a reality. After $0.56 actual earnings per share reported by Activision Blizzard, Inc. for the previous quarter, Wall Street now forecasts -16.07% negative EPS growth.

Since May 16, 2018, it had 0 buys, and 3 selling transactions for $4.14 million activity. $1.39 million worth of Activision Blizzard, Inc. (NASDAQ:ATVI) was sold by ZACCONI RICCARDO on Wednesday, May 16.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts